A nurse is collecting data from a client who has a spinal cord injury with heterotopic ossifications. Which of the following findings should the nurse expect?

Increased intracranial pressure involves elevated cerebral fluid volume, impaired venous outflow, reduced cerebral perfusion pressure, and risk of brain tissue herniation. Positioning plays a critical role in optimizing venous drainage, reducing intracranial pressure, and maintaining adequate oxygen delivery to brain tissues.

Rationale:

A. Prone positioning increases intrathoracic pressure and can obstruct venous return from the brain, worsening intracranial pressure. It also compromises airway access and oxygenation in neurologically unstable clients. Increased venous congestion and impaired cerebral drainage can further elevate intracranial pressure.

B. Elevating the head of the bed to approximately 30 degrees promotes optimal cerebral venous drainage and reduces intracranial pressure. This position enhances jugular venous outflow while maintaining adequate cerebral perfusion. Improved venous return and reduced intracranial volume pressure help prevent secondary brain injury.

C. Flat positioning decreases venous drainage from the brain and increases intracranial blood volume, worsening intracranial pressure. It promotes cerebral congestion and reduces the effectiveness of gravity-assisted venous return. This leads to increased intracranial blood volume and impaired cerebral perfusion dynamics.

D. Trendelenburg position significantly increases intracranial pressure by promoting head-directed blood flow and impairing venous drainage. This position is contraindicated in clients with elevated intracranial pressure. It exacerbates cerebral congestion and reduces effective intracranial pressure control mechanisms.

Spasm-induced urinary incontinence in spinal cord injury results from neurogenic bladder, involuntary detrusor contractions, impaired urinary control, and disrupted sacral reflex pathways. Management focuses on reducing bladder spasms, increasing bladder capacity, and preventing urinary retention, infection, and upper urinary tract complications.

Rationale:

A. Oxybutynin is an anticholinergic medication commonly prescribed for neurogenic bladder with spasm-induced urinary incontinence. It suppresses involuntary detrusor muscle contractions, increases bladder storage capacity, and reduces urinary urgency episodes. Therapeutic effects improve bladder control and decrease excessive detrusor activity in spinal cord injury clients.

B. Dulaglutide is a glucagon-like peptide-1 receptor agonist used in management of type 2 diabetes mellitus. It improves glycemic control through delayed gastric emptying and enhanced insulin secretion. This medication has no therapeutic role in treating urinary incontinence or neurogenic bladder dysfunction following spinal cord injury.

C. Montelukast sodium is a leukotriene receptor antagonist primarily prescribed for asthma and allergic rhinitis management. It reduces airway inflammation and bronchoconstriction but does not affect bladder smooth muscle activity. The medication lacks effectiveness for detrusor spasms and neurologic urinary dysfunction associated with spinal cord injuries.

D. Glatiramer acetate is an immunomodulatory medication used to reduce relapse frequency in multiple sclerosis. Its therapeutic action targets immune-mediated neurologic inflammation rather than bladder muscle overactivity. This medication is unrelated to treatment of neurogenic bladder or involuntary urinary spasms in spinal cord injury clients.